Home › Compare › LDXHF vs EQR

LDXHF vs EQR: Dividend Comparison 2026

LDXHF yields 1238.39% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LDXHF wins by $124493861.49M in total portfolio value
10 years
LDXHF
LDXHF
● Live price
1238.39%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$124493861.54M
Annual income
$107,429,031,462,338.22
Full LDXHF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — LDXHF vs EQR

📍 LDXHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLDXHFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LDXHF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LDXHF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LDXHF
Annual income on $10K today (after 15% tax)
$105,263.16/yr
After 10yr DRIP, annual income (after tax)
$91,314,676,742,987.48/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, LDXHF beats the other by $91,314,676,738,333.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LDXHF + EQR for your $10,000?

LDXHF: 50%EQR: 50%
100% EQR50/50100% LDXHF
Portfolio after 10yr
$62246930.79M
Annual income
$53,714,515,733,906.91/yr
Blended yield
86.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LDXHF
No analyst data
Altman Z
-3.3
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LDXHF buys
0
EQR buys
0
No recent congressional trades found for LDXHF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLDXHFEQR
Forward yield1238.39% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$124493861.54M ✓$47.8K
Annual income after 10y$107,429,031,462,338.22 ✓$5,475.61
Total dividends collected$123225412.32M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: LDXHF vs EQR ($10,000, DRIP)

YearLDXHF PortfolioLDXHF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$134,539$123,839.01$11,380$679.82+$123.2K → LDXHF
2$1,701,076$1,557,119.40$13,014$837.25+$1.69M → LDXHF
3$20,219,975$18,399,823.95$14,961$1,036.20+$20.21M → LDXHF
4$226,038,135$204,402,761.69$17,297$1,289.22+$226.02M → LDXHF
5$2,377,382,925$2,135,522,120.49$20,121$1,613.15+$2377.36M → LDXHF
6$23,535,021,639$20,991,221,908.63$23,561$2,030.84+$23535.00M → LDXHF
7$219,391,496,761$194,209,023,607.94$27,783$2,573.54+$219391.47M → LDXHF
8$1,926,711,724,815$1,691,962,823,279.82$33,013$3,284.39+$1926711.69M → LDXHF
9$15,948,439,325,295$13,886,857,779,743.26$39,547$4,223.51+$15948439.29M → LDXHF
10$124,493,861,540,404$107,429,031,462,338.22$47,791$5,475.61+$124493861.49M → LDXHF

LDXHF vs EQR: Complete Analysis 2026

LDXHF — Stock

Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

Full LDXHF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LDXHF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LDXHF vs SCHDLDXHF vs JEPILDXHF vs OLDXHF vs KOLDXHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.